Survivin Modulators: An Updated Patent Review (2011 - 2015)

E-ISSN： 2212-3970|11|2|152-169

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.11, Iss.2, 2016-04, pp. : 152-169

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Updated Patent Therapeutic Agents Targeting MMPs

Recent Patents on Anti-Cancer Drug Discovery, Vol. 7, Iss. 1, 2012-01 ,pp. : 74-101

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of resistance to trastuzumab: an updated review

By Zhang Yan Zhang Jinsheng

The Chinese-German Journal of Clinical Oncology, Vol. 9, Iss. 11, 2010-11 ,pp. : 660-665

Springer Publishing Company

Access to resources Recommend Favorite

Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies

By Xu Lei Zhou Xin Xu Lin Yin Rong

Tumor Biology, Vol. 35, Iss. 2, 2014-02 ,pp. : 1661-1669

Springer Publishing Company

Access to resources Recommend Favorite

Topoisomerase I and II Inhibitors: A Patent Review

Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, Iss. 4, 2016-11 ,pp. : 401-423

Bentham Science Publishers

Access to resources Recommend Favorite

Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature

Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, Iss. 1, 2016-02 ,pp. : 2-66

Bentham Science Publishers

Access to resources Recommend Favorite